ESMO 2024: Fecal Microbiota Transplantation vs Placebo in Patients Receiving ... - UroToday
The TACITO trial preliminary results show FMT increased 1-year PFS rate in mRCC patients receiving pembrolizumab + axitinib, meeting primary endpoint with 66.7% PFS in FMT vs. 35% in placebo. FMT also prolonged PFS and OS, with 52% ORR in FMT vs. 28% in placebo, though no complete responders. FMT was well-tolerated, requiring longer follow-up and further investigation.
Reference News
ESMO 2024: Fecal Microbiota Transplantation vs Placebo in Patients Receiving ... - UroToday
The TACITO trial preliminary results show FMT increased 1-year PFS rate in mRCC patients receiving pembrolizumab + axitinib, meeting primary endpoint with 66.7% PFS in FMT vs. 35% in placebo. FMT also prolonged PFS and OS, with 52% ORR in FMT vs. 28% in placebo, though no complete responders. FMT was well-tolerated, requiring longer follow-up and further investigation.